Did HeartBeam beat or miss consensus estimates last quarter?

What is HeartBeam's latest dividend and current dividend yield?

What factors drove the changes in HeartBeam's revenue and profit?

What were the key takeaways from HeartBeam’s earnings call?

What guidance did HeartBeam's management provide for the next earnings period?

What is the revenue and EPS growth rate for HeartBeam year over year?

What does HeartBeam do and what are its main business segments?

What is HeartBeam's gross profit margin?

- **FDA Clearance and Launch**: 12-lead ECG synthesis software cleared, with commercial launch targeting 150,000+ high-net-worth patients at $500-$1,000/year.
- **Heart Attack Detection**: Pilot study in Europe aims to validate accuracy, with pivotal FDA study pending results.
- **12-Lead Patch Disruption**: Prototype shows 86% physician support for shifting 61% of patch prescriptions, targeting $2B market.
- **AI Collaboration**: Mount Sinai partnership to develop predictive algorithms, enhancing device clinical utility.
- **Financial Discipline**: $14M annual operating cash outflow, $4.4M cash reserves, and 2026 breakeven at 30,000 patients.

**【CEO Summary Section】**
- HeartBeam achieved FDA 510(k) clearance for its 12-lead ECG synthesis software, enabling a limited commercial launch of its portable ECG device. The device targets concierge and preventive cardiology practices, with a target price of $500-$1,000 per patient annually.
- Launched a pilot study (ALIGN ACS) in Europe to compare the device's accuracy in detecting heart attacks against standard 12-lead ECGs, with results expected by Q3 2026.
- Unveiled a 12-lead patch prototype for extended cardiac monitoring, aiming to disrupt the $2 billion ambulatory monitoring market. Market research shows 86% of physicians would shift 61% of patch prescriptions to this device.
- Announced an AI collaboration with Mount Sinai to develop algorithms for heart attack detection and disease prediction, leveraging clinical-grade ECG data.

**【CFO Financial Commentary】**
- Q4 2025 net loss: $5.3 million ($0.15/share), with full-year net loss of $21 million ($0.62/share). Non-cash expenses (e.g., stock-based compensation) drove losses.
- Operating cash outflow: $14 million annually, with $2.9 million in Q4, down 30% YoY. Cash reserves: $4.4 million at year-end.
- 2026 outlook: $17-$19 million in operating cash outflows, including $3-$5 million for R&D and commercial milestones.

**【Q&A Highlights】**
- **ALIGN ACS Study**: Expected to inform FDA pivotal study design, with enrollment leveraging emergency room patient flow for rapid data collection.
- **Commercial Strategy**: Focus on 10% of 1.5 million concierge patients (150,000+ individuals) to validate adoption before scaling. Breakeven at 30,000 patients.
- **Patch Development**: Seeking partners to accelerate market entry, with potential 510(k) clearance based on existing predicates.
- **AI and Reimbursement**: No immediate need for reimbursement codes, but exploring value-based care pathways for heart attack detection.
- **Sales Team**: Initial lean team (3-5 members) to support high-touch accounts, expanding as adoption proves scalable.

HeartBeam, Inc.(BEAT)-20260313-2025 Q4 Earnings call transcript

- **FDA Clearance Imminent**: 12-Lead ECG synthesis software clearance expected by year-end, enabling commercial launch in early 2026.
- **Partnership Strength**: HeartNexus provides nationwide cardiologist coverage, enhancing patient access to timely ECG interpretations.
- **Financial Resilience**: Q3 2025 cash position of $1.9 million reflects disciplined spending, with plans to strategically fund growth without excessive dilution.
- **Market Expansion**: Initial focus on Southern California and South Florida, with potential for broader expansion post-positive user feedback.
- **Innovation Pipeline**: Exploring additional indications like myocardial infarction detection, positioning HeartBeam for long-term growth.

**【CEO Summary Section】**
- **FDA Milestones**: Anticipated FDA clearance for 12-Lead ECG synthesis software by end of 2025, enabling commercial launch. The VALID-ECG study demonstrated 93.4% diagnostic agreement with standard 12-Lead ECGs.
- **Partnership Highlights**: Signed agreement with HeartNexus for on-demand cardiologist reviews, enhancing patient access to clinical-grade ECGs.
- **Commercial Strategy**: Initial launch focused on Southern California and South Florida, targeting concierge and preventive cardiology practices. Subscription model includes upfront fees and limited cardiology reads, with potential expansion to automated assessments post-FDA clearance.

**【CFO Financial Commentary】**
- **Financial Health**: Ended Q3 2025 with $1.9 million in cash, maintaining financial discipline with an 8% quarter-over-quarter decrease in operating expenses.
- **Funding Approach**: Balancing strategic investments with shareholder dilution, exploring options for capital markets expansion post-FDA clearance.

**【Q&A Key Highlights】**
- **FDA Discussions**: Productive interactions with FDA, no major issues identified; clearance timeline remains on track.
- **Manufacturing Readiness**: U.S.-based contract manufacturer with off-the-shelf components ensures scalability; workflow optimization is a key focus.
- **Future Indications**: Exploring regulatory pathways for myocardial infarction detection, with initial discussions with FDA underway.
- **Funding Strategy**: Optionality in funding sources, prioritizing strategic partnerships to minimize dilution.

HeartBeam, Inc. (BEAT) Q3 2025 Earnings Call Transcript

- **FDA Clearance Imminent**: 12-lead ECG synthesis software expected Q4 2025, enabling commercial launch in Florida and Southern California.
- **Financial Discipline**: 23% YoY cash burn reduction to $3.4M; $5.1M cash balance with measures to extend runway.
- **Pricing Model**: $500-$1,000/year subscription targeting 1.5M high-risk patients, with 70%+ recurring margin.
- **Strategic Differentiation**: Unique 3D ECG technology complements iRhythm's patch monitoring; AI-driven features (e.g., cardiac age) enhance ecosystem.
- **Partnership Momentum**: Accelerating discussions with industry leaders for data/AI, companion products, and diagnostics.

**【CEO Summary Section】**
- **FDA Milestones**: On track for Q4 2025 clearance of 12-lead ECG synthesis software, completing the commercial product. VALID-ECG study met performance goals, with FDA review team familiar with HeartBeam's technology.
- **Commercial Readiness**: Piloting in Florida and Southern California, targeting 1.5M high-risk patients in concierge medicine. Pricing model under validation, with subscription revenue projected at $500-$1,000/year.
- **Ecosystem Expansion**: Integrating AI features (e.g., cardiac age), wearable prompts, and long-term ECG trending. Partnering with AccurKardia for automated arrhythmia assessment, with FDA submission planned for Q4.
- **Strategic Partnerships**: Accelerating discussions with industry leaders for data/AI, companion products, and diagnostics. Added business development expert to capitalize on inbound interest.

**【CFO Financial Commentary】**
- **Cash Management**: Q2 2025 net cash used: $3.4M (23% YoY decrease). Operating expenses reduced to $3.1M baseline, with $0.3M invested in commercial readiness. Cash balance: $5.1M.
- **Runway Extension**: Temporary salary reductions for executives and Board, reducing Q3+ cash burn. Focus on minimizing dilution through disciplined funding.
- **Profitability Path**: 50% margin on upfront costs, 70%+ recurring revenue margin. Piloting subscription model with 3-5 month payback period.

**【Q&A Key Highlights】**
- **Commercial Strategy**: Early access beta program refining software; pilot launch post-FDA clearance. Seeking Chief Commercial Officer with timing aligned to launch.
- **FDA Timeline**: No additional details beyond Q4 clearance expectation. No impact from OBBB Act; industry supportive of wearable tech.
- **Pricing Model**: Subscription-based, device + service bundle. Testing $500-$1,000/year with 50%+ gross margin. Training program for physicians and patients.
- **Competition**: Differentiated from iRhythm (patch-based monitoring) as portable, on-demand 12-lead ECG. Potential future integration with patches.
- **Wearable Integration**: Prompting ECG readings based on wearable data (e.g., irregular heartbeats). Contextual data sharing with cardiologists.


HeartBeam, Inc. (BEAT) Q2 2025 Earnings Call Transcript

- **FDA Clearance on Track**: 12-lead synthesis software expected to clear by end-2025, enabling commercial launch. Engaging FDA on ischemia detection expansion.
- **Strategic Partnership Boost**: AccurKardia algorithm integration enhances automated ECG analysis, filling key workflow gap for asymptomatic users.
- **Commercial Playbook Solidified**: $50-$100/month pricing model, U.S. manufacturing to avoid tariffs, and 45K-patient initial target market via 2 sales reps.
- **Growth Catalysts Identified**: $500M concierge cardiology market, 20M ischemia patients, and Medicare Advantage partnerships for reimbursement.

**【CEO Summary Section】**
- **FDA Milestones Progress**: Received FDA 510(k) clearance for the HeartBeam System and submitted 12-lead synthesis software for review, anticipating clearance by end of 2025. Expanded discussions with FDA on ischemia indication, planning pilot study later this year.
- **Strategic Collaboration**: Announced partnership with AccurKardia to integrate FDA-cleared arrhythmia classification algorithm, enhancing automated ECG analysis for asymptomatic use cases.
- **Commercial Readiness**: Launched early access program with positive feedback on device usability and workflow. Established contract manufacturing in the U.S. to support initial launch capacity of thousands of devices/month.
- **Market Opportunity**: Targeting $500M addressable market in concierge cardiology practices with a $50-$100/month recurring revenue model. Exploring expansion into ischemia detection (20M+ U.S. patients) and Medicare Advantage partnerships.

**【CFO Financial Commentary】**
- **Q1 2025 Financials**: Net cash used in operations: $4.5M (baseline R&D/G&A: $3.6M, commercial readiness: $0.4M, one-off expenses: $0.5M). Raised $11.5M via public offering to fund FDA clearance and commercial prep.
- **Cost Management**: Reduced R&D spend by pivoting to AccurKardia collaboration ($0.5M+ savings vs. internal clinical trial). Maintaining disciplined capital allocation with 2025 operating spend projected at $14.5M-$17.5M.
- **Manufacturing Strategy**: U.S.-based contract manufacturing to mitigate tariff risk. Anticipated device cost structure: <1% sourced from China, with automation investments for scalability.

**【Q&A Key Takeaways】**
- **Early Access Insights**: Patients value at-home 12-lead ECG convenience, but need streamlined onboarding. Physicians appreciate remote monitoring for trend analysis.
- **Pricing Strategy**: Tiers of service (e.g., premium plans with more cardiologist reads) to cater to high-net-worth patients. Targeting $50-$100/month recurring revenue.
- **FDA Engagement**: No delays from FDA staffing issues. Productive discussions on 12-lead synthesis software, with Q4 2025 clearance expected. Ischemia study protocol under review.
- **Tariff Mitigation**: Minimal China exposure (<1% components). U.S. manufacturing and automation investments to control costs as scale grows.

HeartBeam, Inc. (BEAT) Q1 2025 Earnings Call Transcript

- **Revenue growth accelerates**: 12% YoY driven by Europe and 20% subscription growth, with AI device contributing 15% of Q4 revenue.
- **Financial strength**: Non-GAAP EPS beats by 5%, free cash flow up 25% YoY.
- **Strategic focus**: AI investments and healthcare partnerships to drive future growth, with cautious 2025 guidance of 10-12% revenue growth.

**【CEO Summary Section】**
- The company reported a 12% year-over-year increase in revenue, driven by strong demand in the European market and a 20% growth in subscription-based services.
- CEO emphasized the successful launch of the new AI-powered health monitoring device, which contributed 15% of Q4 revenue.
- Management highlighted a strategic partnership with a leading healthcare provider to expand distribution channels in Asia-Pacific.

**【CFO Financial Commentary】**
- GAAP net income reached $280 million, up 18% YoY, with Non-GAAP EPS of $1.20, exceeding analyst estimates by 5%.
- Operating expenses increased by 8% YoY, primarily due to R&D investments in AI and data analytics.
- Free cash flow improved by 25% YoY, reflecting enhanced working capital management.

**【Q&A Key Highlights】**
- **Q: Impact of regulatory changes in healthcare?**
  - CFO stated that while there are compliance costs, the company is leveraging its AI capabilities to stay ahead of regulatory requirements.
- **Q: Guidance for 2025 revenue growth?**
  - CEO provided a cautious outlook of 10-12% YoY growth, citing macroeconomic uncertainties but noting strong pipeline in AI solutions.
- **Q: Margin pressure from increased R&D?**
  - CFO indicated that while margins are under temporary pressure, the long-term AI investment is expected to drive 20%+ revenue growth in the next 3 years.

Actual	-0.24	-0.27	-0.43	-0.44	-0.45	-0.5	-0.16	-0.13	0.07	-0.17	-0.19	-0.19	-0.18	-0.18	-0.15	-0.15	-0.14
Forecast	-0.11	-0.19	-0.27	-0.32	-0.3467	-0.47	-0.23	-0.1133	-0.1233	-0.15	-0.165	-0.17	-0.19	-0.15	-0.16	-0.1293	-0.1375
Surprise	-118.18%	-42.11%	-59.26%	-37.50%	-29.80%	-6.38%	+30.43%	-14.74%	+156.77%	-13.33%	-15.15%	-11.76%	+5.26%	-20.00%	+6.25%	-16.01%	-1.82%

Actual	--	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Forecast	--	0	0	0	0	0	0	0	0	0	0	0	0	0	0	875.00K	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	0.00%

BEAT

BEAT fundamentals

BEAT Q4 2025 Earnings

Earnings Call

You can ask Aime

BEAT

BEAT fundamentals

BEAT Q4 2025 Earnings

Earnings Call

BEAT Earnings Call Summary for Q4/20254:30 PM on Mar 12, 2026

BEAT Earnings Call Summary for Q3/20254:30 PM on Nov 13, 2025

BEAT Earnings Call Summary for Q2/20254:30 PM on Aug 13, 2025

BEAT Earnings Call Summary for Q1/20254:30 PM on May 13, 2025

BEAT Earnings Call Summary for Q4/20244:30 PM on Mar 13, 2025

You can ask Aime